Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ISRCTN12078460) titled 'Real-world experience of patients with IgA nephropathy treated with sparsentan through an Early Access Program in the UK' on Sept. 16.
Study Type: Observational
Study Design:
Cohort study
Primary Sponsor: Vifor International AG
Condition:
Immunoglobulin A (IgA) nephropathy
Urological and Genital Diseases
Intervention:
Participants are not assigned to any treatment or intervention as part of this study. Clinical and laboratory data are collected from routine medical records for patients with Immunoglobulin A (IgA) nephropathy. Information collected may include patient demographics, medical history, disease ...